# Panitumumab and Irinotecan for Malignant Gliomas

> **NCT01017653** · PHASE2 · TERMINATED · sponsor: **Annick Desjardins** · enrollment: 16 (actual)

## Conditions studied

- Malignant Glioma of Brain

## Interventions

- **DRUG:** Irinotecan
- **DRUG:** Panitumumab

## Key facts

- **NCT ID:** NCT01017653
- **Lead sponsor:** Annick Desjardins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-02
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** study did not reach benchmark efficacy rule at 16 subjects
- **Last updated:** 2013-09-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01017653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01017653, "Panitumumab and Irinotecan for Malignant Gliomas". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01017653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*